Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2005 pubmed 241 citations

The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes.

Niyonsaba. François F; Ushio. Hiroko H; Nagaoka. Isao I; Okumura. Ko K; Ogawa. Hideoki H

Key Findings

  • LL-37 and beta‑defensins 2‑4 trigger keratinocytes to secrete IL‑18, peaking around 3 hours.
  • The secretion is enhanced when peptides are mixed together and in calcium‑rich (more differentiated) skin cells.
  • IL‑18 release occurs via p38 and ERK1/2 MAPK pathways, not through caspase‑1 or JNK signaling.

Practical Outcomes

  • For DIY skin‑care or anti‑aging experiments, using LL‑37 may boost inflammatory signaling (IL‑18) rather than just antimicrobial protection. This could be a double‑edged sword: it might help fight infections but could also aggravate inflammatory skin conditions. Users should be cautious about topical LL‑37 use and monitor for signs of irritation or flare‑ups.

Summary

The study shows that the skin peptide LL-37 (and some related defensins) makes skin cells release a signaling molecule called IL-18 by turning on specific cell pathways (p38 and ERK). This happens quickly (within a few hours) and works better when the peptides are combined. The effect does not need the usual enzyme (caspase‑1) that usually helps release IL‑18.

Abstract

In addition to its physical barrier against invading microorganisms, the skin produces antimicrobial peptides, human beta-defensins (hBDs) and cathelicidin LL-37, that participate in the innate host defense. Because IL-18 is produced by keratinocytes and involved in skin diseases in which hBDs and LL-37 are highly expressed, we hypothesized that these peptides would activate keratinocytes to secrete IL-18. We found that hBD-2, -3, and -4 and LL-37, but not hBD-1, activated normal human keratinocytes to secrete IL-18; this secretion reached peak strength at 3 h. In addition, the combination of peptides resulted in a synergistic effect on IL-18 secretion. We also revealed that hBD-2, -3, and -4 and LL-37 increased IL-18 mRNA expression, and that IL-18 secretion was more enhanced in keratinocytes differentiated in vitro with high Ca2+-containing medium. Furthermore, because IL-18 secretion induced by hBDs and LL-37 could not be suppressed by caspase-1 or caspase family inhibitors, and because these peptides failed to increase caspase-1 activity, we suggest that hBD- and LL-37-induced IL-18 secretion is probably via a caspase-1-independent pathway. To determine the molecular mechanism involved, we demonstrated that IL-18 secretion was through p38 and ERK1/2 MAPK pathways, because the inhibitors of p38 and ERK1/2, but not JNK, almost completely nullified IL-18 secretion. Moreover, hBD-2, -3, and -4 and LL-37 could induce the phosphorylation of p38 and ERK1/2, but not JNK. Thus, the ability of hBDs and LL-37 to induce IL-18 secretion by keratinocytes provides a new mechanism for these peptides in innate immunity and an understanding of their role in the pathogenesis of skin disorders.

Study Information

Provider

pubmed

Year

2005

Date

2005-08-01T00:00:00.000Z

DOI

10.4049/jimmunol.175.3.1776

Citations

241

References

60